CN102440986B - 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 - Google Patents
牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 Download PDFInfo
- Publication number
- CN102440986B CN102440986B CN201010299279.XA CN201010299279A CN102440986B CN 102440986 B CN102440986 B CN 102440986B CN 201010299279 A CN201010299279 A CN 201010299279A CN 102440986 B CN102440986 B CN 102440986B
- Authority
- CN
- China
- Prior art keywords
- arctigenin
- bone marrow
- group
- chemotherapy
- chemicals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 title claims abstract description 64
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 title claims abstract description 64
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 title claims abstract description 64
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 title claims abstract description 64
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000001185 bone marrow Anatomy 0.000 title claims abstract description 10
- 239000000126 substance Substances 0.000 title claims description 14
- 230000005855 radiation Effects 0.000 title claims description 13
- 229940079593 drug Drugs 0.000 title abstract description 10
- 230000003405 preventing effect Effects 0.000 title abstract description 5
- 230000001629 suppression Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 238000002512 chemotherapy Methods 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 27
- 206010065553 Bone marrow failure Diseases 0.000 claims description 21
- 230000003039 myelosuppressive effect Effects 0.000 claims description 13
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 230000001096 hypoplastic effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 210000003714 granulocyte Anatomy 0.000 abstract description 19
- 230000003448 neutrophilic effect Effects 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000007086 side reaction Methods 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 16
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 13
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical group CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 12
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 10
- 229960003668 docetaxel Drugs 0.000 description 10
- 229960003685 imatinib mesylate Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 201000002364 leukopenia Diseases 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 230000002607 hemopoietic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000006053 animal diet Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 238000009863 impact test Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- -1 lignan compound Chemical class 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010042121 probasin Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010299279.XA CN102440986B (zh) | 2010-10-08 | 2010-10-08 | 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 |
| PCT/CN2011/080543 WO2012045282A1 (zh) | 2010-10-08 | 2011-10-08 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
| CN201180046435.4A CN103209693B (zh) | 2010-10-08 | 2011-10-08 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
| EP11830238.9A EP2626071B1 (en) | 2010-10-08 | 2011-10-08 | Arctigenin for use in preventing or treating bone marrow suppression |
| AU2011313667A AU2011313667B2 (en) | 2010-10-08 | 2011-10-08 | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction |
| KR1020137011283A KR101512495B1 (ko) | 2010-10-08 | 2011-10-08 | 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 |
| JP2013532041A JP5744213B2 (ja) | 2010-10-08 | 2011-10-08 | 赤血球減少に関連する疾病の予防又は治療用薬物の製造におけるアルクチゲニンの用途 |
| HK14100853.0A HK1188122B (en) | 2010-10-08 | 2011-10-08 | Arctigenin for use in preventing or treating bone marrow suppression |
| US13/878,381 US20130190394A1 (en) | 2010-10-08 | 2011-10-08 | Applications Of Arctigenin In Formulating Drugs For Preventing Or Treating Diseases Related To Red Blood Cell Reduction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010299279.XA CN102440986B (zh) | 2010-10-08 | 2010-10-08 | 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102440986A CN102440986A (zh) | 2012-05-09 |
| CN102440986B true CN102440986B (zh) | 2014-12-03 |
Family
ID=45927226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010299279.XA Expired - Fee Related CN102440986B (zh) | 2010-10-08 | 2010-10-08 | 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 |
| CN201180046435.4A Expired - Fee Related CN103209693B (zh) | 2010-10-08 | 2011-10-08 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180046435.4A Expired - Fee Related CN103209693B (zh) | 2010-10-08 | 2011-10-08 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130190394A1 (enExample) |
| EP (1) | EP2626071B1 (enExample) |
| JP (1) | JP5744213B2 (enExample) |
| KR (1) | KR101512495B1 (enExample) |
| CN (2) | CN102440986B (enExample) |
| AU (1) | AU2011313667B2 (enExample) |
| WO (1) | WO2012045282A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103209693A (zh) * | 2010-10-08 | 2013-07-17 | 鲁南制药集团股份有限公司 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397547B (zh) * | 2010-09-19 | 2013-06-12 | 山东新时代药业有限公司 | 一种抗癌药物组合物 |
| CN103027906B (zh) * | 2011-10-08 | 2015-11-11 | 鲁南制药集团股份有限公司 | 牛蒡子苷元在治疗贫血疾病中的应用 |
| KR20140139073A (ko) * | 2012-03-26 | 2014-12-04 | 구라시에제약 주식회사 | 항암제 |
| CN103446100A (zh) * | 2012-05-29 | 2013-12-18 | 鲁南制药集团股份有限公司 | 牛蒡子苷元的舌下含服制剂 |
| JP5696191B2 (ja) * | 2013-04-27 | 2015-04-08 | クラシエ製薬株式会社 | 抗癌幹細胞剤 |
| ES2698620T3 (es) | 2013-10-21 | 2019-02-05 | Lunan Pharmaceutical Group Corp | Icaritina para uso en la prevención o el tratamiento de la hematocitopenia |
| CN104546823B (zh) * | 2013-10-21 | 2019-08-30 | 鲁南制药集团股份有限公司 | 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途 |
| JP6234553B2 (ja) * | 2014-04-10 | 2017-11-22 | クラシエ製薬株式会社 | 抗癌剤および副作用軽減剤 |
| JP6197077B1 (ja) * | 2016-07-14 | 2017-09-13 | クラシエ製薬株式会社 | 抗癌剤、放射線増感剤および食品組成物 |
| CN110623960B (zh) * | 2018-06-22 | 2022-08-19 | 成都山权江生物科技有限公司 | 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用 |
| JP7675547B2 (ja) * | 2021-04-01 | 2025-05-13 | クラシエ株式会社 | 酸化ｌｄｌ増加抑制剤および酸化ｌｄｌ増加抑制用食品組成物 |
| CN119462619B (zh) * | 2024-11-06 | 2025-10-24 | 浙江大学 | 一种橙酮类化合物及其医药用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1560265A (zh) * | 2004-02-26 | 2005-01-05 | 广州中医药大学 | 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法 |
| CN102210653A (zh) * | 2010-04-03 | 2011-10-12 | 鲁南制药集团股份有限公司 | 牛蒡苷元的微乳制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| JP2009523805A (ja) * | 2006-01-17 | 2009-06-25 | シグナル ファーマシューティカルズ，エルエルシー | ＴＮＦα、ＰＤＥ４及びＢ−ＲＡＦの阻害剤、それらの組成物及びそれらの使用法 |
| CN101036643A (zh) * | 2006-03-13 | 2007-09-19 | 海南盛科天然药物研究院有限公司 | 含牛蒡子苷元的药物组合物及其制备方法 |
| CN101134031B (zh) | 2006-08-30 | 2012-05-09 | 山东绿叶天然药物研究开发有限公司 | 牛蒡子苷元在制备治疗或预防慢性肾功能衰竭及肾纤维化的药物中的用途 |
| CN102440986B (zh) * | 2010-10-08 | 2014-12-03 | 鲁南制药集团股份有限公司 | 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 |
-
2010
- 2010-10-08 CN CN201010299279.XA patent/CN102440986B/zh not_active Expired - Fee Related
-
2011
- 2011-10-08 KR KR1020137011283A patent/KR101512495B1/ko active Active
- 2011-10-08 US US13/878,381 patent/US20130190394A1/en not_active Abandoned
- 2011-10-08 WO PCT/CN2011/080543 patent/WO2012045282A1/zh not_active Ceased
- 2011-10-08 JP JP2013532041A patent/JP5744213B2/ja active Active
- 2011-10-08 EP EP11830238.9A patent/EP2626071B1/en not_active Not-in-force
- 2011-10-08 CN CN201180046435.4A patent/CN103209693B/zh not_active Expired - Fee Related
- 2011-10-08 AU AU2011313667A patent/AU2011313667B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1560265A (zh) * | 2004-02-26 | 2005-01-05 | 广州中医药大学 | 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法 |
| CN102210653A (zh) * | 2010-04-03 | 2011-10-12 | 鲁南制药集团股份有限公司 | 牛蒡苷元的微乳制剂 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103209693A (zh) * | 2010-10-08 | 2013-07-17 | 鲁南制药集团股份有限公司 | 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012045282A1 (zh) | 2012-04-12 |
| JP2013542205A (ja) | 2013-11-21 |
| EP2626071A1 (en) | 2013-08-14 |
| KR101512495B1 (ko) | 2015-04-15 |
| CN103209693A (zh) | 2013-07-17 |
| EP2626071A4 (en) | 2014-04-02 |
| EP2626071B1 (en) | 2016-01-13 |
| HK1188122A1 (en) | 2014-04-25 |
| CN102440986A (zh) | 2012-05-09 |
| JP5744213B2 (ja) | 2015-07-08 |
| CN103209693B (zh) | 2015-10-07 |
| US20130190394A1 (en) | 2013-07-25 |
| AU2011313667B2 (en) | 2015-08-27 |
| KR20130093125A (ko) | 2013-08-21 |
| AU2011313667A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102440986B (zh) | 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途 | |
| CN103861079A (zh) | 一种清热止痛消瘤中药组合物 | |
| CN103179967A (zh) | 抗肿瘤药物组合物 | |
| CN104688722B (zh) | 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途 | |
| CN102133385A (zh) | 生姜与白胡椒组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
| CN101342185A (zh) | 连翘酯苷在制备抗肿瘤化疗增敏减毒药物或抗艾滋病增敏减毒药物中的应用 | |
| CN102370645B (zh) | 一种抗癌药物组合物 | |
| CN1284599C (zh) | 一种消肿瘤的药物及其制备工艺 | |
| CN102166336A (zh) | 枇杷叶与生姜组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
| CN104189782A (zh) | 一种抗肿瘤的药物组合物 | |
| CN105380956A (zh) | 一种治疗白血病的含艾德拉尼的药物组合物及应用 | |
| CN106038702B (zh) | 抗疲劳的组合物及其制备方法和应用 | |
| CN104857180B (zh) | 抗疲劳及提高免疫力的组合物及其制备方法和应用 | |
| CN105982888A (zh) | 一种含青蒿素和紫杉醇的联合用药物及其用途 | |
| CN102580065A (zh) | 虎眼万年青皂甙osw-i口服抗癌制剂及其制备方法 | |
| CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
| CN104840528A (zh) | 一种防治骨髓抑制的药物组合物及其用途 | |
| CN103784492A (zh) | 具有抗肿瘤作用的铜锤玉带草提取物及其应用 | |
| CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
| CN102309493B (zh) | 一种抗癌药物组合物 | |
| CN102166337A (zh) | 生姜与旋覆花组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
| CN108355029A (zh) | 一种治疗放化疗后呕吐的药物及其制备方法 | |
| Behzad et al. | Artemisia annua | |
| CN106421154A (zh) | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 | |
| CN103202875B (zh) | 参归丸在制备抑制肿瘤细胞的药物及联合化疗药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 |